[Hyperlipoproteinemia in primary gout and asymptomatic hyperuricemia]

Area of Science:

• Lipid metabolism and cardiovascular health
• Gout and hyperuricemia research
• Clinical biochemistry and diagnostics

Context:

• Gout and asymptomatic hyperuricemia are linked to metabolic disturbances.
• Lipoprotein profiles play a crucial role in cardiovascular risk assessment.
• Understanding lipid abnormalities in these conditions is vital for patient management.

Purpose:

• To investigate and compare lipoprotein patterns in patients with primary gout and asymptomatic hyperuricemia against healthy controls.
• To quantify the prevalence of abnormal high-density-lipoprotein (HDL), low-density-lipoprotein (LDL), and very-low-density-lipoprotein (VLDL) in these patient groups.

Summary:

• Lipid electrophoresis revealed significant abnormalities in HDL, LDL, and VLDL levels in both gout (n=147) and asymptomatic hyperuricemia (n=700) groups compared to controls.
• Approximately 80% of patients showed increased LDL, 35% decreased HDL, and elevated VLDL was observed in 72% of gout patients and 54% of hyperuricemia patients.
• Pathological changes in all lipoproteins were found in 23% of gout patients and 20% of hyperuricemia patients, with normal lipid metabolism rare (2.7% and 4.8% respectively).

Impact:

• Highlights the high prevalence of dyslipidemia in gout and asymptomatic hyperuricemia, underscoring their shared metabolic derangements.
• Suggests that asymptomatic hyperuricemia carries similar lipid abnormality risks to diagnosed gout.
• Emphasizes the need for routine lipid profiling and cardiovascular risk management in patients with elevated uric acid levels.